DNA-guided medicine at the point of care

Most medicines are prescribed without knowing the patient's genotype, so adverse reactions and treatment failure are often discovered only after the fact. Precision Medicine International makes genetic information visible at the point of care, turning one genomic analysis into evidence-based, DNA-guided recommendations for clinicians and their patients.

XY Leap™ Omics Platform is clinical decision support software, registered with Medsafe, New Zealand's medicines and medical devices regulator. One analysis informs care for life, across more than 1,100 guided therapeutics:

900+ medicines with dosing guidance and phenoconversion safety checks

150 traditional medicines matched to each patient's toxicogenomic profile

75 nutraceuticals for personalized preventive and anti-inflammatory protocols

Three ways to work with us: platform access for clinicians, consumers and institutions; DNA-guided reporting at the point of care; and precision medicine education for doctors and pharmacists.

A finished platform, not a concept: 13 years of development and validation by a practicing clinician | Registered with Medsafe | Complete technical file, clinical evaluation, verification and validation | Backed by clinicians and private investors

Thermo Fisher Scientific, our global strategic partner. Supported by New Zealand Trade and Enterprise (NZTE). Headquartered in Christchurch, New Zealand, serving clinicians and organizations worldwide.

Clinicians and hospitals

XY Leap gives clinicians DNA-guided prescribing support across medical and surgical specialties: dosing guidance, drug-gene interaction alerts and phenoconversion checks, alongside personalized nutrition, exercise and sleep insights. Reports update as new evidence is published. XY Leap supports, and does not replace, clinical judgment.

Pharmacies and longevity

Through pharmacies and wellness partners, XY Leap gives consumers personalized prevention and longevity insights: nutrition, exercise, sleep and environmental exposure guidance based on their own genetics, with reports that stay current as new research is published.

Workforce health

For energy, mining, agriculture and aviation, XY Leap helps occupational health teams understand how each worker's genetics may affect their response to medicines and to common workplace exposures, such as fuels, solvents, dusts and agrichemicals, and supports individualized nutrition and recovery guidance.

Defense health

For military medical teams, XY Leap supports DNA-guided prescribing alongside individualized nutrition, training and recovery guidance, helping to keep personnel healthy and ready.

Meet the Team

  • Dr Andrew Winnington

    Co-founder and Chief Executive Officer

    Board Director

    Andrew is a NASA-trained family physician who built XY Leap over 13 years of clinical practice to bring medical genomics into everyday clinical and lifestyle decisions.

  • Craig Morris

    Board Chairman and Advisor

    Craig is a senior finance and governance leader from international banking and asset management, including Chief Financial Officer roles for regulated institutions in Switzerland.

  • Dr Jonathan Chen

    Medical Advisory Board

    Dual specialist in Intensive Care Medicine and Internal Medicine, with experience spanning preventive, primary, secondary, and tertiary healthcare. He has worked across diverse clinical and leadership settings, combining academic depth with a pragmatic and practical focus on patient-centred outcomes.

  • Dr Maneesh Deva

    Medical Advisory Board

    Clinical Lead Innovation, Institute of Innovation and Improvement, Te Whatu Ora Health New Zealand, Waitematā. Honorary Lecturer (Paediatrics), School of Medicine and Health Sciences, University of Auckland. General Paediatrician, Royal Australasian College of Physicians (2014). Medical Advisor Kidshealth.org.nz. Convenor NZ Paediatric Forum.

  • Dr Ben Simpson

    Medical Advisory Board

    Consultant Anaesthetist, Te Whatu Ora.

  • Dr Richard Goldsmith

    Medical Advisory Board

    FACEM with diverse clinical experience within Australasia; from large tertiary level trauma centres to sole practice in small rural towns. Also, significant prehospital and retrieval experience. Current Head of Unit at regional emergency department in South Australia.

  • “The new version is perfect compared to other pharmacogenomics tests. It was really impressive for all doctors who ordered your trials”

    Dr Junichi Taguchi, MD, PhD, Chief Medical Director, Tokyo Midtown Clinic

  • “Amazing... the reports update themselves as new medical research come to light… absolutely incredible with regards to the diversity of information they give me.” 

    Gabe Rijpma, Former Senior Director of Health at Microsoft Asia